Lates News

On August 26, AbbVie announced that it has reached a definite agreement with Gilgamesh Pharmaceuticals to acquire their investigational drug bretisilocin, a 5-HT2A receptor agonist and 5-HT releaser, for the treatment of moderate to severe depression (MDD).